Vascular Imaging With Ferumoxytol as a Contrast Agent
- 1 September 2015
- journal article
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 205 (3) , W366-W373
Abstract
OBJECTIVE. Ferumoxytol is increasingly reported as an alternative to gadolinium-based contrast agents for MR angiography (MRA), particularly for patients with renal failure. This article summarizes...Keywords
This publication has 44 references indexed in Scilit:
- Superparamagnetic Iron Oxide Nanoparticles in Biomedicine: Applications and Developments in Diagnostics and TherapyRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2013
- MRI Using Ferumoxytol Improves the Visualization of Central Nervous System Vascular MalformationsStroke, 2011
- 4D phase contrast MRI at 3 T: Effect of standard and blood‐pool contrast agents on SNR, PC‐MRA, and blood flow visualizationMagnetic Resonance in Medicine, 2009
- Superparamagnetic Iron Oxide Nanoparticles: Diagnostic Magnetic Resonance Imaging and Potential Therapeutic Applications in Neurooncology and Central Nervous System Inflammatory Pathologies, a ReviewJournal of Cerebral Blood Flow & Metabolism, 2009
- Utility of USPIO-enhanced MR imaging to identify inflammation and the fibrous cap: A comparison of symptomatic and asymptomatic individualsEuropean Journal of Radiology, 2009
- Ferumoxytol for Treating Iron Deficiency Anemia in CKDJournal of the American Society of Nephrology, 2008
- Identifying Inflamed Carotid Plaques Using In Vivo USPIO-Enhanced MR Imaging to Label Plaque MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- In Vivo Detection of Macrophages in Human Carotid AtheromaStroke, 2004
- A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRIJournal of X-Ray Science and Technology, 2003
- European Society of Urogenital Radiology guidelines on administering contrast mediaAbdominal Radiology, 2003